The non-exclusive license agreement covers the delivery of multiple Slonomics-based DNA libraries.
As per the agreement, MorphoSys will receive committed annual funding for the delivery of libraries and stands to receive milestone and royalty payments on each product emerging from the collaboration.
The libraries will encode a range of protein classes, excluding antibodies, and will be used by its partner for drug discovery.
The Slonomics technology enables the precise construction of protein libraries comprising defined mixtures of amino acids at pre-determined positions with unprecedented speed.
MorphoSys CEO Simon Moroney said this fourth alliance around the Slonomics technology further illustrates the value of the platform.
"Slonomics is a powerful method for making libraries of all types, and this agreement exemplifies the commercial opportunity it creates for us beyond the antibody field," Moroney added.